Ginkgo Bioworks Holdings Inc vs Liberty Global Ltd Class C — how do they compare? Ginkgo Bioworks Holdings Inc trades at $9 (market cap $590.53M), while Liberty Global Ltd Class C trades at $10.46 (market cap $3.59B). The key difference: Liberty Global Ltd Class C is far larger — about 6.1× Ginkgo Bioworks Holdings Inc's market cap, and Ginkgo Bioworks Holdings Inc is trading nearer its 52-week high, Liberty Global Ltd Class C nearer its low. Which is the better fit depends on your goals.
| DNA | LBTYK | |
|---|---|---|
Market Cap | $590.53M | $3.59B |
Sector | Health | Technology |
52-Week High | $16.14 | $12.67 |
52-Week Low | $5.48 | $10.07 |
Enterprise Value | $627.78M | $10.88B |
Signals from Pluang's Aura AI — not financial advice
DNA trades at $9.05, down 0.44% on the day, reflecting ongoing investor caution. The technical outlook is bearish, while fundamentals show significant losses with a net income margin of -201.05% and negative cash flows. Recent earnings have been mixed, missing estimates in two of the last three quarters. Analyst sentiment is divided, with a slight lean toward buy ratings amid high volatility and operational challenges.
The outlook remains challenging due to persistent losses and cash burn, though analyst coverage suggests potential long-term value. Key risks include execution missteps and intense competition in biotechnology. Investment appeal hinges on future profitability improvements and successful business model execution.
LBTYK trades at $10.54, up 2.63% today, but technical indicators are bearish with a negative net income margin of -109.66% for 2026. The stock shows a low P/S of 0.71 and P/B of 0.37, indicating potential undervaluation. Recent news highlights the planned 2027 spin-off and Amsterdam listing of Ziggo Group as a key catalyst. Analyst consensus is strongly positive with 69% buy ratings, though earnings have been volatile with a significant miss in Q4 2025.
The outlook is mixed: the spin-off offers upside potential, but persistent losses and high debt pose risks. Investors should weigh the sum-of-the-parts valuation opportunity against operational challenges and market volatility. The stock remains speculative with a bearish technical trend despite positive analyst sentiment.
Trailing returns across standard periods
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →Liberty Global is a world leader in converged broadband, video, and mobile communications. It operates large-scale fiber and 5G networks across Europe, providing essential digital services to millions of customers.
Read more on LBTYK →